

<p>94-283250/35 B07 (B05) MITU 93.01.14  MITSUBISHI KASEI CORP *JP 06211645-A  93.01.14 93JP-004810 (94.08.02) A61K 9/127, 9/14, 47/30  Freeze-dried liposome preparation - contains cyclic inulo-  oligosaccharide as stabiliser  C94-129180</p>	<p>B(4-C2X, 12-M6, 12-M11F)</p>
<p>Freeze-dried liposome preparation includes cyclic inulo-oligo  saccharide.  The prepn. pref. contains another saccharide gp. and/or peptide  gp. Cyclic inulo-oligo saccharide comprises pref. cyclic structure of  2-8 fructose by binding beta-2,1. Saccharide is pref. selected from  trehalose, saccharose, lactose, maltose, glucose and fructose.  Peptide gp. is pref. selected from gelatin, alubumin and casein.  Membrane substances of liposome are phospholipid e.g.  phosphatidylcholine, phosphatidylethanol amine,  phosphatidylinositol, phosphatidylserine and sphingomyeline  derived from egg yolk, soybeans, other animals and plants;  diparmytilphosphatidylcholine (DPPC),  distearylphosphatidylcholine (DSPC) and  dipalmitoylphosphatidylethanol amine (DPPE). Drugs sealed in  liposome are anti-cancer agent e.g. adriamycin; antiviral agent e.g.  interferon and peptide hormone, e.g. insulin and calcitonin;  enzymatic agent, e.g. alkali phosphatase; amino succharide</p>	<p>antibiotics, e.g. gentamicin and streptomycin. The wt. ratio of cyclic  inulo-oligo saccharide to lipid is 1/10-2/1, pref. 1/10-1/1. The wt. ratio  of other saccharide gp. to cyclic inulo-oligo saccharide is 1/2-1/1, and  the wt. ratio of peptide gp. to cyclic inulo-oligo saccharide is 1/6-1/2.  The wt. ratio of cyclic inulo-oligo saccharide, or total amt. of other  saccharide gp. and peptide gp. to lipid is 1/10-1/1.  USE/ADVANTAGE - The freeze-dried liposome prepn. is stably  preserved over a long period of time due to the addn. of cyclic  inulo-oligo saccharide as stabiliser. The dia. of the liposome is not  changed even when dissolved in water in use, almost completely  keeping the drug sealed in a liposome. (4pp Dwg.No.0/0)</p>